4.0 Article

Extensive rod and cone photoreceptor-cell degeneration in rat models of giant axonal neuropathy: implications for gene therapy of human disease

Journal

OPHTHALMIC GENETICS
Volume 42, Issue 5, Pages 600-603

Publisher

TAYLOR & FRANCIS INC
DOI: 10.1080/13816810.2021.1923036

Keywords

Giant axonal neuropathy (GAN); intermediate filaments (IF); GAN knock-out (KO) and knock-in (KI) rat models; Gigaxonin; rod and cone photoreceptor cell (PR-cell) degeneration; photoreceptor cell (PR-cell) loss in hereditary retinal degeneration; human GAN

Funding

  1. Hannah's Hope Fund for Giant Axonal Neuropathy
  2. NIH National Institute of Neurological Disorders and Stroke [NS087175, NS095515]
  3. NIH National Institute of Child Health and Human Development [HD040127, U54HD079124]

Ask authors/readers for more resources

The study identified progressive degeneration of rod and cone photoreceptor cells in the retinas of newly developed GAN rat models, suggesting a possible contribution to visual impairment in human GAN patients. The current gene therapy clinical trial for GAN treatment does not specifically address this retinal cell degeneration, indicating the need for future treatment protocols to potentially include strategies targeting the protection of these cells.
Background: Giant axonal neuropathy (GAN; ORPHA: 643; OMIM# 256850) is a rare, hereditary, pediatric neurodegenerative disorder associated with intracellular accumulations of intermediate filaments (IFs). Validation of therapeutic efficacy and viral vector delivery systems with GAN knockout (KO) mouse models has provided the springboard for the development of a viral vector being delivered intrathecally in an ongoing Phase I gene therapy clinical trial for the treatment of children with GAN (https://clinicaltrials.gov/ct2/show/NCT02362438). Purpose: To characterize the ocular pathologic phenotype of newly developed GAN rat models. Materials and Methods: Microscopic examination of eyes at various timepoints. Results: We noted the unexpected finding of progressive and extensive degeneration of rod and cone photoreceptor (PR) cells in the retinas of GAN rat models. Conclusion: This PR-cell loss in rat models of GAN raises the possibility that PR-cell loss may contribute to the visual impairment observed in human GAN. The intrathecal viral vector employed in the ongoing Phase I gene therapy clinical trial for the treatment of children with GAN was not specifically designed to address PR-cell degeneration. If GAN-associated PR-cell loss is present and clinically significant in humans, then future treatment protocols for GAN may need to include a gene transfer approach or combinatorial treatment strategy that also targets retinal PR cells.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available